| 1 |
2022 |
Nicolas Rosa, Femke Speelman-Rooms, Jan B. Parys, Geert Bultynck. Modulation of Ca2+ signaling by antiapoptotic Bcl-2 versus Bcl-xL: From molecular mechanisms to relevance for cancer cell survival, Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2022; 1877: 188791188791.
https://doi.org/10.1016/j.bbcan.2022.188791 |
| 2 |
2023 |
Ryan M. Finnegan, Ahmed M. Elshazly, Nipa H. Patel, Liliya Tyutyunyk-Massey, Tammy H. Tran, Vishnu Kumarasamy, Erik S. Knudsen, David A. Gewirtz. The BET inhibitor/degrader ARV-825 prolongs the growth arrest response to Fulvestrant + Palbociclib and suppresses proliferative recovery in ER-positive breast cancer, Frontiers in Oncology. 2023; 12: 966441.
https://doi.org/10.3389/fonc.2022.966441 |
| 3 |
2023 |
Sheeba Jacob, Richard Kurupi, Anthony C. Faber. 2023; 105.
https://doi.org/10.1016/B978-0-12-822833-3.00009-7 |
| 4 |
2021 |
Pratik Pal, Dinesh Thummuri, Dongwen Lv, Xingui Liu, Peiyi Zhang, Wanyi Hu, Saikat K. Poddar, Nan Hua, Sajid Khan, Yaxia Yuan, Xuan Zhang, Daohong Zhou, Guangrong Zheng. Discovery of a Novel BCL-XL PROTAC Degrader with Enhanced BCL-2 Inhibition, Journal of Medicinal Chemistry. 2021; 64: 14230.
https://doi.org/10.1021/acs.jmedchem.1c00517 |
| 5 |
2023 |
Jiaming Zhang, Baofang Zhang, Congli Pu, Jiarui Cui, Kexin Huang, Hongbo Wang, Yingchao Zhao. Nanoliposomal Bcl-xL proteolysis-targeting chimera enhances anti-cancer effects on cervical and breast cancer without on-target toxicities, Advanced Composites and Hybrid Materials. 2023; 6: 78.
https://doi.org/10.1007/s42114-023-00649-w |
| 6 |
2024 |
Aleša Bricelj, Yuen Lam Dora Ng, Martina Gobec, Robert Kuchta, Wanyi Hu, Špela Javornik, Miha Rožič, Michael Gütschow, Guangrong Zheng, Jan Krönke, Christian Steinebach, Izidor Sosič. Design, Synthesis, and Evaluation of BCL‐2 Targeting PROTACs, Chemistry – A European Journal. 2024; 30: e202400430.
https://doi.org/10.1002/chem.202400430 |
| 7 |
2024 |
Sajid Khan, Lin Cao, Janet Wiegand, Peiyi Zhang, Maria Zajac-Kaye, Frederic J. Kaye, Guangrong Zheng, Daohong Zhou. PROTAC-Mediated Dual Degradation of BCL-xL and BCL-2 Is a Highly Effective Therapeutic Strategy in Small-Cell Lung Cancer, Cells. 2024; 13: 528.
https://doi.org/10.3390/cells13060528 |
| 8 |
2024 |
Sajid Khan, Lin Cao, Janet Wiegand, Peiyi Zhang, Maria Zajac-Kaye, Frederic J. Kaye, Guangrong Zheng, Daohong Zhou. 2024;
https://doi.org/10.1101/2024.02.27.582353 |
| 9 |
2023 |
Selvi Jegatheeson, Claire Cannon, Caroline Mansfield, Joanne Devlin, Andrew Roberts. Sensitivity of canine hematological cancers to BH3 mimetics, Journal of Veterinary Internal Medicine. 2023; 37: 236.
https://doi.org/10.1111/jvim.16587 |
| 10 |
2023 |
Sajid Khan, Patrick Kellish, Nick Connis, Dinesh Thummuri, Janet Wiegand, Peiyi Zhang, Xuan Zhang, Vivekananda Budamagunta, Nan Hua, Yang Yang, Umasankar De, Lingtao Jin, Weizhou Zhang, Guangrong Zheng, Robert Hromas, Christine Hann, Maria Zajac-Kaye, Frederic J. Kaye, Daohong Zhou. Co-targeting BCL-XL and MCL-1 with DT2216 and AZD8055 synergistically inhibit small-cell lung cancer growth without causing on-target toxicities in mice, Cell Death Discovery. 2023; 9: 1.
https://doi.org/10.1038/s41420-022-01296-8 |
| 11 |
2023 |
Chuanxu Liu, Xinyu Ding, Gaoyang Li, Youping Zhang, Yubao Shao, Linyi Liu, Wenhao Zhang, Yujie Ma, Wenbin Guan, Lifeng Wang, Zhongli Xu, YungTing Chang, Yongqiang Zhang, Biao Jiang, Qianqian Yin, Rong Tao. Targeting Bcl-xL is a potential therapeutic strategy for extranodal NK/T cell lymphoma, iScience. 2023; 26: 107369107369.
https://doi.org/10.1016/j.isci.2023.107369 |
| 12 |
2022 |
Arvind Negi, Anne Sophie Voisin‐Chiret. Strategies to Reduce the On‐Target Platelet Toxicity of Bcl‐xL Inhibitors: PROTACs, SNIPERs and Prodrug‐Based Approaches, ChemBioChem. 2022; 23: e202100689.
https://doi.org/10.1002/cbic.202100689 |
| 13 |
2023 |
Xuyang Zhao, Yifan Chen, Huang Su, Liqin Zhang. From classic medicinal chemistry to state‐of‐the‐art interdisciplinary medicine: Recent advances in proteolysis‐targeting chimeras technology, Interdisciplinary Medicine. 2023; 1: e20230004.
https://doi.org/10.1002/INMD.20230004 |
| 14 |
2024 |
Akash Vikal, Rashmi Maurya, Brij Bihari Patel, Rajeev Sharma, Preeti Patel, Umesh K. Patil, Balak Das Kurmi. Protacs in cancer therapy: mechanisms, design, clinical trials, and future directions, Drug Delivery and Translational Research. 2024;
https://doi.org/10.1007/s13346-024-01754-z |
| 15 |
2022 |
Pratik Pal, Peiyi Zhang, Saikat K. Poddar, Guangrong Zheng. Patent landscape of inhibitors and PROTACs of the anti-apoptotic BCL-2 family proteins, Expert Opinion on Therapeutic Patents. 2022; 32: 1003.
https://doi.org/10.1080/13543776.2022.2116311 |
| 16 |
2022 |
Sajid Khan, Patrick Kellish, Nick Connis, Dinesh Thummuri, Janet Wiegand, Peiyi Zhang, Xuan Zhang, Vivekananda Budamagunta, Nan Hua, Yang Yang, Umasankar De, Lingtao Jin, Weizhou Zhang, Guangrong Zheng, Robert Hromas, Christine Hann, Maria Zajac-Kaye, Frederic J. Kaye, Daohong Zhou. 2022;
https://doi.org/10.1101/2022.09.12.507616 |
| 17 |
2024 |
Mengyao Wu, Yilan Zhao, Chi Zhang, Kanyi Pu. Advancing Proteolysis Targeting Chimera (PROTAC) Nanotechnology in Protein Homeostasis Reprograming for Disease Treatment, ACS Nano. 2024; 18: 28502.
https://doi.org/10.1021/acsnano.4c09800 |
